SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending as the cybersecurity sector faces a significant sell-off, fueled by fears that Anthropic's Claude Code Security tool could disrupt traditional software. This has sparked intense debate among investors, with many calling the sharp decline an overreaction and a buying opportunity, asserting that Claude's functionality does not directly compete with Crowdstrike's core offerings.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

International Business Machines is experiencing significant volatility, fueled by aggressive put buying and concerns that AI could disrupt its legacy offerings, despite recent strong earnings and strategic advancements in enterprise AI and quantum computing. The community remains divided, with some questioning the sudden decline amid a broader software sector pullback, while others view it as an oversold buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following its FDA approval of BYSANTI for bipolar I disorder and schizophrenia, a significant win highlighted by its New Chemical Entity (NCE) status and patent protection until 2044. The community is actively discussing the company's substantial undervaluation and high potential for a buyout, especially considering prior rejected offers and recent analyst target upgrades.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is experiencing a significant downturn, with community debate raging over whether fears of AI-driven obsolescence, particularly from Anthropic's Claude Code Security, justify the extensive sell-off across the cybersecurity sector. While some predict further declines due to AI disruption, many view the stock as fundamentally oversold and a generational buying opportunity.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as it hits new all-time lows following news of a 12% workforce layoff, intensifying community speculation about its financial viability, potential for bankruptcy, and future dilution amidst a challenging EV market.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending due to a sharp sell-off, fueled by widespread community discussion around AI, particularly Anthropic's Claude, potentially disrupting traditional enterprise software. Despite the ETF hitting multi-year lows and whispers of a "SaaSpocalypse," many investors are now considering the oversold sector as a long-term opportunity amidst perceived market overreaction.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending due to its proactive integration of AI in payments and robust earnings report, while the community actively debates both the disruptive potential of AI in financial services and the indirect market impact of proposed credit card regulations.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to widespread reports of attracting unsolicited takeover interest, with potential suitors eyeing either the entire company or valuable assets like Venmo. The community is actively debating prospective acquirers and speculating on buyout prices significantly above current levels, fueled by perceptions of the company's undervaluation and strong cash flow despite its recent stock slump and impending leadership change.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to significant market frustration over its steep decline despite reporting GAAP profitability and a focus on prudent, lower-risk growth in its latest guidance. While some investors fear broader fintech sector weakness and macro headwinds, many in the community believe the stock is severely undervalued and poised for a rebound, highlighting its AI-driven model and institutional demand for its ABS deals.

Blackboxstocks, Inc. engages in the operation of a financial technology and social media platform. It offers real-time proprietary analytics and news for stock and option traders. The company was founded by Gust Kepler, Eric Pharis and David Kyle on October 4, 2011 and is headquartered in Dallas, TX.

Blackboxstocks Inc

The impending merger with REalloys Inc. is driving immense interest in BLBX, as REalloys actively builds out a North American mine-to-magnet rare earth supply chain. Community discussions are highlighting the recent effectiveness of the merger's S-4, substantial U.S. EXIM Bank financing, strategic board additions including high-profile defense and finance leaders, and key international partnerships, positioning the combined entity as a significant player in critical minerals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Brokers Lift Earnings Estimates for KPTI

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report issued...

Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade

The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday...

Promising Nuclear Stocks To Consider - February 16th

Oklo, NuScale Power, Centrus Energy, BWX Technologies, Nano Nuclear Energy, Karyopharm Therapeutics, and Lightbridge are the seven Nuclear stocks to watch today, according to MarketBeat's stock...

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Misses Expectations By $3.45 EPS

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) announced its earnings results on Thursday. The company reported ($5.71) EPS for the quarter, missing the consensus estimate of ($2.26) by...

Karyopharm Therapeutics Q4 Earnings Call Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) executives highlighted upcoming late-stage clinical catalysts, continued revenue growth for its multiple myeloma franchise, and a tighter cost structure during...

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +1.47% and +3.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat...

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights...

Uncovering Potential: Karyopharm Therapeutics's Earnings Preview

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

KPTI
Karyopharm Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KPTI News

KPTIKaryopharm Therapeutics Inc